AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.30

AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

This AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of the 26th day of February, 2024 (the “Execution Date”), between XXXX XXXXXXXXX, M.D., Ph.D. (“Executive”) and Syndax Pharmaceuticals, Inc. (the “Company”) and supplements the terms of that certain executive employment agreement by and between the Parties, dated as of March 30, 2023 (the “Agreement”). Capitalized terms used and not otherwise defined herein shall have the meaning ascribed to such terms in the Agreement.

RECITALS

A.The Company employs Executive as its President, Head of Research and Development, upon the terms and conditions set forth in the Agreement.

B.The Compensation Committee of the Company’s Board of Directors approved certain changes to terms of Executive’s employment and the parties are entering this Amendment specifying such changes.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual promises contained herein, the Company and Executive agree as follows:

1.1Executive’s Target Performance Bonus as set forth in the Agreement is hereby amended to a threshold of up to fifty percent (50%) of Executive’s Annual Base Salary.

1.2“Change in Control Benefits Period” means the period of eighteen (18) months commencing on the Termination Date.

1.3“Change in Control Severance Period” means the period of eighteen (18) months commencing on the Termination Date.

1.4Effectiveness of Agreement. This Amendment shall be effective on the Execution Date.

* * * * *

IN WITNESS WHEREOF, the parties have executed this Amendment on the Execution Date written above.

Syndax Pharmaceuticals, Inc.

EXECUTIVE

By:

/s/ Xxxx X. Xxxxxxxx

By:

/s/ Xxxx Xxxxxxxxx, M.D., Ph.D.

Name:

Xxxx X. Xxxxxxxx

Name:

Xxxx Xxxxxxxxx, M.D., Ph.D.

Title:

General Counsel

1.